Scholarlink

<p>Hepatocellular carcinoma (HCC) relapse remains high after curative-intent treatment due to occult minimal residual disease. Circulating tumour DNA (ctDNA) has emerged as a noninvasive biomarker. Systematic search of MEDLINE, EMBASE and the Cochrane Library up to November 2024 identified studies evaluating plasma ctDNA in non-metastatic HCC patients undergoing curative-intent treatment. Hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using random-effects models; sensitivity and specificity for predicting recurrence were summarised. Ten retrospective studies (<i>n</i> = 793) met inclusion criteria. Postoperative ctDNA positivity was associated with shorter RFS (HR 4.48; 95% CI 2.56–7.82; I² = 78%; <i>p</i> &lt; 0.001) and worse OS (HR 2.99; 95% CI 1.94–4.61; I² = 47%; <i>p</i> &lt; 0.001). Baseline ctDNA detection predicted reduced RFS (HR 3.54; 95% CI 1.97–6.38; I² = 35%; <i>p</i> &lt; 0.001). Sensitivity ranged 33–82% and specificity 41–100%, reflecting methodological heterogeneity. Leave-one-out analyses confirmed robustness. Plasma ctDNA is a potent prognostic marker of recurrence and survival in non-metastatic HCC. Prospective trials incorporating ctDNA could optimise postoperative surveillance and guide adjuvant therapy selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Isabella R. Buonopane,
  • Erick F. Saldanha,
  • Júnior Samuel Alonso de Menezes,
  • Lucas Diniz da Conceição,
  • Camila Mariana de Paiva Reis,
  • Luís Felipe Leite,
  • Thiago Francischetto,
  • Renata D’Alpino Peixoto,
  • Tiago Biachi de Castria

摘要

Hepatocellular carcinoma (HCC) relapse remains high after curative-intent treatment due to occult minimal residual disease. Circulating tumour DNA (ctDNA) has emerged as a noninvasive biomarker. Systematic search of MEDLINE, EMBASE and the Cochrane Library up to November 2024 identified studies evaluating plasma ctDNA in non-metastatic HCC patients undergoing curative-intent treatment. Hazard ratios (HRs) and 95% confidence intervals (CIs) for recurrence-free survival (RFS) and overall survival (OS) were pooled using random-effects models; sensitivity and specificity for predicting recurrence were summarised. Ten retrospective studies (n = 793) met inclusion criteria. Postoperative ctDNA positivity was associated with shorter RFS (HR 4.48; 95% CI 2.56–7.82; I² = 78%; p < 0.001) and worse OS (HR 2.99; 95% CI 1.94–4.61; I² = 47%; p < 0.001). Baseline ctDNA detection predicted reduced RFS (HR 3.54; 95% CI 1.97–6.38; I² = 35%; p < 0.001). Sensitivity ranged 33–82% and specificity 41–100%, reflecting methodological heterogeneity. Leave-one-out analyses confirmed robustness. Plasma ctDNA is a potent prognostic marker of recurrence and survival in non-metastatic HCC. Prospective trials incorporating ctDNA could optimise postoperative surveillance and guide adjuvant therapy selection.